Immunoglobulin Or Antibody Binds An Oligosaccharide Structure Other Than Nucleic Acid Patents (Class 435/329)
-
Patent number: 6627740Abstract: The present invention provides a monoclonal antibody which binds to a polypeptide as set forth in SEQ ID NO: 1 as described herein.Type: GrantFiled: August 24, 2001Date of Patent: September 30, 2003Inventors: Toshio Hirano, Tsuneyasu Kaisho
-
Patent number: 6596689Abstract: A class of proteoglycans containing fucosylated acidic glycans, e.g., as produced by marine sponges and sea urchin embryos, have been found to stimulate selective proliferation of mammalian natural killer (NK) cells and &ggr;&dgr;T cells. These compounds are useful as pharmaceuticals, particularly as immunostimulants, e.g., in the treatment of cancer and viral infections.Type: GrantFiled: December 6, 2000Date of Patent: July 22, 2003Inventor: Gradimir Misevic
-
Publication number: 20030087418Abstract: The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of a organisms to antimicrobial agents.Type: ApplicationFiled: August 9, 2001Publication date: May 8, 2003Applicant: Diagnostic Hybrids, Inc.Inventors: David R. Scholl, Yung T. Huang, Patricia Gail Ray Goodrum
-
Patent number: 6485970Abstract: The present invention relates generally to immunointeractive molecules and their use inter alia in the detection and/or purification of T-cell antigen binding molecules (TABMs). The ability to determine the presence and levels of particular TABMs provides a useful diagnostic procedures for a variety of disease conditions.Type: GrantFiled: May 10, 2000Date of Patent: November 26, 2002Inventors: Robert E. Cone, George M. Georgiou, Colin H. Little
-
Patent number: 6475775Abstract: The invention describes nucleic acids encoding the PARG protein, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acids, and antibodies relating thereto. Methods and products for using such nucleic acids and polypeptides also are provided.Type: GrantFiled: May 8, 2000Date of Patent: November 5, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Jan Saras, Petra Franzén, Pontus Aspenström, Ulf Hellman, Leonel Jorge Gonez, Carl-Henrik Heldin
-
Patent number: 6391635Abstract: Disclosed herein are method for producing hydridoma cell lines producing monoclonal human natural IgM antibodies and hybridoma cells produced by the methods. The antibodies are the monoclonal equivalents of circulating human natural antibodies.Type: GrantFiled: May 23, 2000Date of Patent: May 21, 2002Assignee: Institute for Human Genetics and BiochemistryInventor: Toby C. Rodman
-
Patent number: 6316256Abstract: Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and/or adhesion function. The fusion protein is transferred to a cell by binding to a lipidated protein, which has been incorporated into the cell membrane. Methods for using cells which have undergone protein transfer according to the present methods are also disclosed. This includes use in a cancer vaccine, use for treatment of cancer or autoimmune disease, and use in determining costimulator threshold levels.Type: GrantFiled: January 3, 2000Date of Patent: November 13, 2001Assignee: TR Associates, L.L.C.Inventors: Mark L. Tykocinski, Aoshuang Chen, Guoxing Zheng
-
Patent number: 6306615Abstract: This invention relates to monoclonal antibodies that recognize modified &bgr;-tubulin isotypes, methods of using such antibodies to detect modified &bgr;-tubulin isotypes, methods of using such antibodies to monitor &bgr;-tubulin modifying agents administered to a patient, methods of using such antibodies to isolate modified &bgr;-tubulin, and methods of detecting the anti-modified &bgr;-tubulin antibodies.Type: GrantFiled: August 19, 1999Date of Patent: October 23, 2001Assignee: Tularik Inc.Inventors: Holger Beckmann, Edit Santha
-
Patent number: 6287568Abstract: This invention includes the conception of T-independent conjugate-vaccines and its application in the induction of antigen specific IgA response. We demonstrated that 1) &agr;(1,6)dextran can elicit a markedly enhanced IgA response in T-cell free mice (20-50 fold higher than in normal mice); 2)co-injection of the molecule with other antigens can enhance the IgA response to the co-antigen; and 3)a dextran-Gag conjugate can elicit the Gag-specific IgA. Thus, the invention identified &agr;(1,6)dextran as a carrier molecule for producing the T-independent conjugates and as an adjuvant for the enhancement of IgA production. The T-independent property of these conjugates makes it especially useful in vaccinations against HIV and other infectious and non-infectious diseases associated with T-cell deficiency.Type: GrantFiled: September 9, 1998Date of Patent: September 11, 2001Assignee: The Trustees of Columbia University in the City of New YorkInventors: Denong Wang, Bernard F. Erlanger, Elvin A. Kabat
-
Patent number: 6204366Abstract: A reshaped human antibody or reshaped human antibody fragment having specificity for human polymorphic epithelial mucin (PEM) is produced by transferring the complementarity determining regions (CDRS) from a murine anti-HMFG hybridoma cell line HMFG1 into a human antibody variable region framework. The reshaped molecule can be used in the treatment or diagnosis of cancer.Type: GrantFiled: May 7, 1993Date of Patent: March 20, 2001Assignee: Unilever Patent Holdings B.V.Inventor: Martine Elisa Verhoeyen
-
Patent number: 6165784Abstract: Methods to detect prion or PrP-Sc protein as an indication of transmissible spongiform encephalopathies (TSEs), including preclinical detection of infected live animals, and postmortem detection methods, are described. In one aspect, the invention is directed to a non-invasive diagnostic assay using third eyelid-associated lymphoid tissue. In another aspect, the invention is directed to monoclonal antibodies that specifically bind a conserved epitope of PrP-Sc protein in fixed or frozen treated tissue.Type: GrantFiled: October 14, 1997Date of Patent: December 26, 2000Assignees: The United States of America as represented by the Secretary of Agriculture, Washington State University Research FoundationInventors: Katherine I. O'Rourke, Donald P. Knowles, Timothy V. Baszler, Steven M. Parish
-
Patent number: 6048537Abstract: Method for preparing purified influenza antigens from a fluid containing influenza virus, comprising the steps of concentration, purification, fragmentation and, where appropriate, inactivation, characterized in that:A. either the purification step entails several ultracentrifugation steps separated by a filtration step,B. or the fragmentation step is performed on the live virus in the presence of an amphiphilic nonionic detergent, followed by a removal of undesirable substances by filtration, retaining all of the viral constituents,or these two steps are carried out in any order.Type: GrantFiled: May 27, 1997Date of Patent: April 11, 2000Assignee: Pasteur Merieux Serums et VaccinsInventors: Jean Michel Violay, Guy Court, Catherine Gerdil, Herve Chalumeau, Patric McVerry
-
Patent number: 6042828Abstract: Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2.Type: GrantFiled: June 27, 1996Date of Patent: March 28, 2000Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai, Yoshihisa Kuwana, Mamoru Hasegawa
-
Patent number: 6015680Abstract: The monoclonal antibody produced by a hybridoma cell strain TRD-L1, -L2 or -L3 which is obtained by the fusion between mouse myeloma cells and spleen cells of a mouse immunized with a human lung adenocarcinoma cell secretion component reacts in a specific fashion with a glycoprotein antigen that has a molecular weight of 200 kD or more (SDS-PAGE) and is present in human lung adenocarcinoma cells. It can be used efficiently in cancer diagnosis.Type: GrantFiled: September 12, 1997Date of Patent: January 18, 2000Assignee: Terumo Kabushiki KaishaInventors: Kouichi Tsuji, Yoshihiro Yoshida, Takashi Uwano
-
Patent number: 6004528Abstract: Improved methods for the diagnosis and treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stemline are provided. These methods are an improvement over previous cancer detection and therapeutic methods because they provide for very early cancer detection and treatment and reduce the likelihood of clinical relapse after treatment.Type: GrantFiled: September 18, 1997Date of Patent: December 21, 1999Inventor: Ivan Bergstein
-
Patent number: 5939532Abstract: Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2.Type: GrantFiled: June 7, 1995Date of Patent: August 17, 1999Assignee: Kyowa Hakko Kogyo Co., LtdInventors: Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai, Yoshihisa Kuwana, Mamoru Hasegawa
-
Patent number: 5892000Abstract: The present invention relates to monoclonal antibodies to advanced glycosylation endproducts formed in vivo and cross-reactive with advanced glycosylation endproducts formed in vitro, and to methods of diagnosis and therapy based thereon. More particularly, the invention is directed to a monoclonal antibody, or an antigen-binding fragment thereof, reactive with in vivo produced advanced glycosylation endproducts (AGEs), which monoclonal antibody or antigen binding fragment thereof demonstrates an immunological binding characteristic of monoclonal antibodies selected from the group consisting of 4G9 as produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626, 2G6 as produced by hydridoma 2G6, deposited with the American Type Culture Collection (ATCC) on Dec. 19, 1995, and assigned Accession Number HB 12008, and BH4 as produced by hydridoma BH4, deposited with the American Type Culture Collection (ATCC) on Dec.Type: GrantFiled: December 29, 1995Date of Patent: April 6, 1999Assignee: Alteon Inc.Inventors: Henry W. Founds, Homayoun Sadeghi
-
Patent number: 5888757Abstract: Disclosed are methods that can be used to (1) measure the level of polysaccharide in a sample; (2) measure the ability of a compound to degrade a polysaccharide; (3) measure the ability of a compound to modulate polysaccharide synthesis; and (4) identify or distinguish a polysaccharide, and hence organism, for diagnostic purposes in clinical medicine or research. The invention stems from Applicant's discovery that polysaccharides have multiple binding sites for polysaccharide binding moieties (PBM, e.g., wheat germ agglutinin (WGA)). In each method, one PBM links the polysaccharide to a substrate, and a tagged PBM is used to detect the polysaccharide. All of these methods can be carried out rapidly and quickly in the wells of a microtiter plate, thus permitting high through-put screening of samples or test compounds.Type: GrantFiled: May 3, 1996Date of Patent: March 30, 1999Assignee: Millennium Pharmaceuticals, Inc.Inventor: Michael Joseph Kuranda
-
Patent number: 5876716Abstract: A monoclonal or other antibody to the carbohydrate antigen Tn can be used to inhibit or slow the progression of AIDS or ARC. The antigen can be used in a vaccine, for immunisation.Type: GrantFiled: December 30, 1994Date of Patent: March 2, 1999Assignee: Bay Development Corporation SAInventors: John-Erik Stig Hansen, Henrik Clausen
-
Patent number: 5817513Abstract: The present invention relates to immunotherapy strategies for the treatment of malignancies. The present immunotherapy strategies have gangliosides as a target. Gangliosides are glycosphingolipids which are present on normal cells and on malignant cells. On malignant cells they are more abundant and expressed in a different organization and conformation. The present invention provides antibodies which recognize these gangliosides, which antibodies are specific, have recurrent idiotypes and have value as immunoregulators. The invention further provides anti-idiotypic antibodies against anti-ganglioside antibodies. These are useful in vaccination strategies.Type: GrantFiled: December 9, 1994Date of Patent: October 6, 1998Assignee: Centro de Inmunologia MolecularInventors: Ana Maria Vazguez Lopez, Angel Mauro Alfonso Fernandez, Rolando Perez Rodriguez, Amparo E. Macias Abraham, Carlos Manuel Alvarez Valcarcel, Maria Eliana Lanio Ruiz
-
Patent number: 5786160Abstract: A novel natural killer cell-specific molecule, designated as PEN5, consisting essentially of a glycoprotein pair called PEN5.alpha. and PEN5.beta., having apparent molecular weights of 120-150 and 210-245 kdal, respectively. Monoclonal antibodies, including immunoreactive fragments and derivatives thereof, that bind to unique epitopes present on this NK cell-specific molecule; hybridomas that produce the monoclonal antibodies; methods of using the antibodies and fragments and derivatives; and methods for detecting and/or removing natural killer cells from a sample containing a mixed population of cells are also provided.Type: GrantFiled: June 7, 1995Date of Patent: July 28, 1998Assignee: Dana-Farber Cancer InstituteInventors: Paul Anderson, Eric Vivier
-
Patent number: 5780032Abstract: Provided is a method for reproducible production of cytokeratin antigen/immunogen. Cytokeratins from whole carcinoma cells are purified by preparative SDS-PAGE. Bands corresponding to cytokeratins 8, 18, and 19 are eluted from the gel, and these cytokeratins are digested to produce fragments in the size range of 10-50 Kd. The invention also relates to use of these fragments as immunogens for the production of antibodies. Furthermore, the invention relates to an immunochemical test kit to detect cancer of epithelial origin in body fluids. The kit comprises cytokeratin fragments produced by the method of the invention and antibodies to these fragments.Type: GrantFiled: June 19, 1996Date of Patent: July 14, 1998Assignee: AB IDL Immunodevelop LabInventors: .ANG.ke Silen, Bo Wiklund
-
Patent number: 5744318Abstract: The present invention relates to monoclonal antibodies to advanced glycosylation endproducts formed in vivo and cross-reactive with advanced glycosylation endproducts formed in vitro, and to methods of diagnosis and therapy based thereon. More particularly, the invention is directed to a monoclonal antibody, or an antigen-binding fragment thereof, reactive with in vivo produced advanced glycosylation endproducts (AGEs), which monoclonal antibody or antigen binding fragment thereof demonstrates an immunological binding characteristic of monoclonal antibody 4G9 as produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626. In a specific embodiment, the 4G9 antibody is used in a sandwich ELISA to detect ApoB-AGE, IgG-AGE, collagen-AGE, serum-AGE peptides and proteins and urinary-AGE peptides and proteins.Type: GrantFiled: December 30, 1994Date of Patent: April 28, 1998Assignee: Alteon Inc.Inventors: Henry W. Founds, Homayoun Sadeghi
-
Patent number: 5730981Abstract: The invention relates to monoclonal antibodies of high avidity, which react specifically with the gangliosides GD3 and GQ1b, and to their use for detecting melanomas and other tumors or tissues expressing GD3 and GQ1b.Type: GrantFiled: October 20, 1994Date of Patent: March 24, 1998Assignee: Behringwerke AktiengesellschaftInventors: Klaus Bosslet, Gerhard Seemann, Wolfgang Dippold
-
Patent number: 5717071Abstract: Cell lines have been produced that secrete human monoclonal antibodies capable of binding to molecules of different bacterial species. These antibodies have been found to be protective against lethal challenges of various bacterial genera. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal antibodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections are included. Prior to filing of this patent application the continuous transformed human cell lines 9B10, 4F10, 4B9, 7D7, and 9C3, described herein, were deposited in the American Type Culture Collection and given the designations CRL 9006, CRL 9007, CRL 9008, CRL 9009, and CRL 9239, respectively.Type: GrantFiled: September 2, 1994Date of Patent: February 10, 1998Assignee: Bristol-Myers Squibb CompanyInventor: Howard V. Raff
-
Patent number: 5688657Abstract: Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse/human chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fragments and derivatives thereof, are useful in immunodiagnosis and immunotherapy of human colon, breast, and ovarian cancer, and for purification of antigens which can serve as immunotherapeutic agents. Methods of detecting the colon carcinoma-associated antigen in a sample, and methods for treating subjects having colon, breast, and ovarian carcinomas are disclosed.Type: GrantFiled: September 12, 1994Date of Patent: November 18, 1997Assignee: International Bio-Immune Systems, Inc.Inventors: Kwong Y. Tsang, Myron Arlen
-
Patent number: 5653977Abstract: The invention provides an anti-idiotypic monoclonal antibody which elicits an immune response in a mammal against the ganglioside GD2 antigen.Type: GrantFiled: October 23, 1995Date of Patent: August 5, 1997Assignee: UAB Research FoundationInventor: Mansoor N. Saleh
-
Patent number: 5639622Abstract: The invention relates to monoclonal antibodies (MAbs) and fragments thereof which bind to defined tumor-associated antigens, principally of small cell lung carcinoma (SCLC), of melanoma, of neuroblastoma and other tumors of neuroectodermal origin, to hybridoma cell lines for the preparation thereof, and to the antigens which can be defined and/or isolated with the aid of these antibodies or antibody fragments. The antibodies, antibody fragments and antigens can be used as diagnostic. aid, active substance or active substance carrier.Type: GrantFiled: June 7, 1995Date of Patent: June 17, 1997Assignee: Behringwerke AktiengesellschaftInventors: Klaus Bosslet, Bernhard Auerbach, Helmut Peters
-
Patent number: 5627067Abstract: Cell lines have been produced that secrete human monclonal antibodies capable of binding to the lipopolysaccharide molecules of selected Pseudomonas aeruginosa IATS serotypes. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal antibodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections are included.Prior to filing of this patent application the continuous transformed human cell lines 1C1, 6D6, and 8H7 described herein were deposited in the American Type Culture Collection and given the designations CRL 8941, 9171, and 9258, respectively.Type: GrantFiled: June 5, 1995Date of Patent: May 6, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Anthony W. Siadak, Mae J. Rosok
-
Patent number: RE37596Abstract: The invention relates to monoclonal antibodies (MAbs) and fragments thereof which bind to defined tumor-associated antigens, principally of small cell lung carcinoma (SCLC), of melanoma, of neuroblastoma and other tumors of neuroectodermal origin, to hybridoma cell lines for the preparation thereof, and to the antigens which can be defined and/or isolated with the aid of these antibodies or antibody fragments. The antibodies, antibody fragments and antigens can be used as diagnostic, aid, active substance or active substance carrier.Type: GrantFiled: June 16, 1999Date of Patent: March 19, 2002Assignee: Dade Behring Marburg GmbHInventors: Klaus Bosslet, Bernhard Auerbach, Helmut Peters